Monitor for pricing and effectiveness of the registration statement. The SPAC has 18 months post-closing to identify and complete a business combination. Track any future 8-K filings for target announcements or business combination agreements.
Executive Summary
Allarity Acquisition Corp. files Amendment No. 2 to its S-1 registration statement for an $80 million SPAC IPO of 8,000,000 units at $10.00/unit, each consisting of one Class A ordinary share and one redeemable warrant. The SPAC is sponsored by ALLR Sponsor LLC, a wholly owned subsidiary of Allarity Therapeutics (ALLR), and will focus on life sciences/biotech targets. No target has been identified. The filing updates the prospectus with current financials and offering details.
Key Financial Metrics
Key Facts
- Offering 8,000,000 units at $10.00/unit for gross proceeds of $80,000,000
- Each unit consists of one Class A ordinary share and one redeemable warrant
- Sponsor ALLR Sponsor LLC (wholly owned by Allarity Therapeutics, ALLR) purchased 3,833,333 founder shares for $25,000
- Sponsor will purchase 2,500,000 private warrants at $1.00/warrant ($2,500,000 aggregate)
- Underwriters have 45-day over-allotment option for up to 1,200,000 additional units
- $80,800,000 ($10.10 per public share) will be deposited in trust account
- 18 months from closing to complete initial business combination
- Focus on life sciences/biotechnology sectors, but not limited to any industry
- No target identified and no substantive discussions initiated
- Working capital deficit of ($112,519) as of May 31, 2026
Financial Impact
IPO gross proceeds of $80,000,000 from units plus $2,500,000 from private warrants; $80,800,000 deposited in trust account; approximately $500,000 available outside trust for working capital
Risk Factors
- No identified acquisition target and no operating history
- 18-month deadline to complete business combination or liquidate
- Sponsor paid $0.0065 per founder share vs $10.00 per unit public offering price, creating misaligned incentives
- Potential conflicts of interest with Allarity Therapeutics (ALLR) management
- Working capital deficit and reliance on IPO proceeds for operations
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001493152-26-045923 |
| Exhibit: ex1-1.htm | 0001493152-26-045923 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | S-1/A | — | awaiting T+20 | — | — |
Oct 6, 2026 19d ago | S-1/A | — | awaiting T+20 | — | — |
Oct 2, 2026 24d ago | S-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers